News and Comments

COULD AGENUS VACCINE FOR GLIOBLASTOMA BE ASSIGNED BREAKTHROUGH DESIGNATION?

  Tuesday, September 17, 2013

AGENUS (AGEN) has extraordinary news. A recent analysis from a Phase 2 trial in patients with newly diagnosed glioblastoma multiforme (GBM) treated with Prophage Series G-100 (HSPPC-96) in combination with the current standard of care (radiation and temozolomide) showed an almost 18 month median progression free survival (PFS), which represents a 160% increase versus current standard of care alone. The results confirm continuation of the positive trends from the Phase 2 HSPPC-96 newly diagnosed GBM trial first reported at the 81st American Association of Neurological Surgeons (AANS) Annual Scientific Meeting in May 2013. More...


Recent News_and_Comments


Archive


Tags